ANL Key Statistics, Chart & Performance
The current stock price of ANL is 10.63 USD. In the past month the price increased by 648.59%. In the past year, price increased by 401.42%.
ANL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ANL. When comparing the yearly performance of all stocks, ANL is one of the better performing stocks in the market, outperforming 99.8% of all stocks.
ANL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ANL. ANL may be in some trouble as it scores bad on both profitability and health.
ANL Financial Highlights
Over the last trailing twelve months ANL reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 78.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.78% | ||
| ROE | -203.53% | ||
| Debt/Equity | 1.05 |
ANL Forecast & Estimates
8 analysts have analysed ANL and the average price target is 9.18 USD. This implies a price decrease of -13.64% is expected in the next year compared to the current price of 10.63.
ANL Ownership
ANL Latest News, Press Relases and Analysis
About ANL
Company Profile
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. The firm is involved in the research and development of pharmaceutical products. The company is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. The company is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. The company is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Company Info
ADLAI NORTYE LTD-ADR
c/o PO Box 309, Ugland House
George Town KY
Employees: 123
Phone: 18482307430
ADLAI NORTYE LTD-ADR / ANL FAQ
What does ADLAI NORTYE LTD-ADR do?
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. The firm is involved in the research and development of pharmaceutical products. The company is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. The company is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. The company is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
What is the current price of ANL stock?
The current stock price of ANL is 10.63 USD. The price increased by 62.79% in the last trading session.
Does ADLAI NORTYE LTD-ADR pay dividends?
ANL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANL stock?
ANL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for ANL stock?
ADLAI NORTYE LTD-ADR (ANL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
Can you provide the ownership details for ANL stock?
You can find the ownership structure of ADLAI NORTYE LTD-ADR (ANL) on the Ownership tab.